Russell Conley: My first infusion of immunotherapy
Russell Conley, Chief Executive Officer at GI Cancer Institute, shared on LinkedIn:
“I am currently receiving my first infusion of immunotherapy. I am so hopeful that it, in combination with the chemotherapy treatments I receive, will eliminate or reduce the inoperable tumors in my abdomen and pelvis.
The efficacy of new treatments like immunotherapies is only proven through clinical trials. However, due to the low incidence of anal cancer, there is currently no evidence as to the effectiveness of this treatment combination for metastatic anal SCC.
Positive thinking helps.
Edit: Despite there being no data for this treatment combination for anal squamous cell carcinoma (SCC) there is positive data from research in head and neck SCC – cancers that also have an overexpression of the p16 protein resulting from human papillomavirus (HPV).
Fortunately the HPV vaccine used in Australia called Gardasil 9 is offered to all Australian children aged about 12 to 13 through the school-based National Immunisation Program.”
Source: Russell Conley/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023